[
  {
    "ts": null,
    "headline": "Why Novo Nordisk Is A Strong Buy Despite Market Concerns",
    "summary": "Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.",
    "url": "https://finnhub.io/api/news?id=3122007dae2978956606ea7a5228db0ac0ef5a4180bc8ae0df8c2091a0d4e554",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740009540,
      "headline": "Why Novo Nordisk Is A Strong Buy Despite Market Concerns",
      "id": 132792928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156718067/image_1156718067.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.",
      "url": "https://finnhub.io/api/news?id=3122007dae2978956606ea7a5228db0ac0ef5a4180bc8ae0df8c2091a0d4e554"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Files For Mixed Shelf Size Not Disclosed - SEC Filing",
    "summary": "Eli Lilly and Co: * ELI LILLY FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SECFILINGSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=c8e495d128de16023b8d488b3f4b95190c31515f4986072ea9626a9ef0f9d350",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739987189,
      "headline": "Eli Lilly Files For Mixed Shelf Size Not Disclosed - SEC Filing",
      "id": 132791524,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * ELI LILLY FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SECFILINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=c8e495d128de16023b8d488b3f4b95190c31515f4986072ea9626a9ef0f9d350"
    }
  },
  {
    "ts": null,
    "headline": "Fat, not muscle: Drugmakers in race for next weight-loss breakthrough",
    "summary": "Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can increase the...",
    "url": "https://finnhub.io/api/news?id=9681ac219bcf4501509d28ac8343888184676bfbcc65a2191036450c3f32074a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739959574,
      "headline": "Fat, not muscle: Drugmakers in race for next weight-loss breakthrough",
      "id": 135358847,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can increase the...",
      "url": "https://finnhub.io/api/news?id=9681ac219bcf4501509d28ac8343888184676bfbcc65a2191036450c3f32074a"
    }
  },
  {
    "ts": null,
    "headline": "Mairs & Power Balanced Fund Q4 2024 Commentary",
    "summary": "The Fund lagged the benchmark composite index, which was up 15.01%, while the Fund underperformed the Morningstar Moderate Allocation peer group, which rose 11.29%.",
    "url": "https://finnhub.io/api/news?id=29975de5785e96be4bca83002c66233baf15555758fed17c910d511ee446c7b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739954400,
      "headline": "Mairs & Power Balanced Fund Q4 2024 Commentary",
      "id": 132784169,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310052459/image_1310052459.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Fund lagged the benchmark composite index, which was up 15.01%, while the Fund underperformed the Morningstar Moderate Allocation peer group, which rose 11.29%.",
      "url": "https://finnhub.io/api/news?id=29975de5785e96be4bca83002c66233baf15555758fed17c910d511ee446c7b6"
    }
  },
  {
    "ts": null,
    "headline": "IWLG: A Good Growth ETF, But Not The Best",
    "summary": "Discover key insights on IWLG, an actively managed ETF with tech focus. Explore its performance vs. SCHG and Russell 1000 Growth.",
    "url": "https://finnhub.io/api/news?id=3099b72d9aa5b1925798f85c189f26728a594a7ab6dcda9c824cf611e1b1ba6f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739942917,
      "headline": "IWLG: A Good Growth ETF, But Not The Best",
      "id": 132783096,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1009092686/image_1009092686.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover key insights on IWLG, an actively managed ETF with tech focus. Explore its performance vs. SCHG and Russell 1000 Growth.",
      "url": "https://finnhub.io/api/news?id=3099b72d9aa5b1925798f85c189f26728a594a7ab6dcda9c824cf611e1b1ba6f"
    }
  },
  {
    "ts": null,
    "headline": "What Top-Performing Healthcare Funds Are Buying Now",
    "summary": "What Top-Performing Healthcare Funds Are Buying Now",
    "url": "https://finnhub.io/api/news?id=3d2d2ef72d3c71a23f0f72c19a9644e3fc2f5bcb257cb503bcfe127751d1e4d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739932200,
      "headline": "What Top-Performing Healthcare Funds Are Buying Now",
      "id": 132784558,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "What Top-Performing Healthcare Funds Are Buying Now",
      "url": "https://finnhub.io/api/news?id=3d2d2ef72d3c71a23f0f72c19a9644e3fc2f5bcb257cb503bcfe127751d1e4d4"
    }
  }
]